Now is not the time to chill drug research and development
July 1, 2020
By Peter J. Pitts
As the COVID-19 pandemic rages on, all eyes are on the United States for smart strategies, treatments and a cure. The good news: Our biopharmaceutical companies have been working around the clock to deliver help as quickly as possible.
Yet, some lawmakers are pushing for a bill that could stifle the desire to invest in lifesaving innovation.
Senators Ron Wyden (D-OR) and Chuck Grassley (R-IA) have been racing to pass their sweeping Prescription Drug Pricing Reduction Act. The measure would effectively impose price controls and massive new taxes on pharmaceutical innovators...
For access to this article please
sign in or
subscribe.
Reader Comments(0)